Skip to main content
    E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.89
    +0.34 (+7.47%)

    Market Cap: $177.16M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    +5.46%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.88
    Range$-1.30 - $-0.36
    6 analysts
    Revenue Consensus
    $-3072380
    Range$-9221050 - $11M
    6 analysts
    Last 12 of 26 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.88$-1.30 - $-0.36--6--
    Sep 26
    Reported Nov 5
    		$-0.94$-0.98$-1.22 - $-0.62+4.08%Beat6
    1
    1
    30d
    		+11.3%
    Jun 26
    Reported Aug 5
    		$-1.01$-1.16$-1.34 - $-0.68+12.93%Beat7
    3
    3
    30d
    		+2.9%
    Mar 26
    Reported May 7
    		$-0.95$-1.02$-1.16 - $-0.67+6.86%Beat7
    2
    2
    30d
    		-126.2%
    Dec 25
    Reported Feb 26
    		$-0.94$-1.32$-2.10 - $-0.60+28.79%Beat6
    3
    1
    30d
    		-3233.3%
    Sep 25
    Reported Nov 6
    		$-1.06$-0.96$-1.13 - $-0.74-10.42%Miss4
    0
    2
    30d
    		-202.9%
    Jun 25
    Reported Aug 6
    		$-1.04$-0.86$-0.98 - $-0.72-20.93%Miss3
    2
    1
    30d
    		-167.1%
    Mar 25
    Reported May 8
    		$-0.42$-0.77$-0.92 - $-0.70+45.45%Beat4
    No revisions (30d)
    		-161.8%
    Dec 24
    Reported Feb 27
    		$0.03N/A-+104.48%Beat5
    2
    1
    30d
    		+110.3%
    Sep 24
    Reported Nov 5
    		$-0.35$-0.62-+43.55%Beat5
    No revisions (30d)
    		-134.3%
    Jun 24
    Reported Aug 13
    		$1.55$0.33$-0.41 - $0.77+369.70%Beat4
    No revisions (30d)
    		+298.7%
    Mar 24
    Reported May 7
    		$0.68$-0.47$-1.10 - $-0.01+244.68%Beat5
    No revisions (30d)
    		+423.8%
    Dec 23
    Reported Mar 13
    		$-0.29$-0.17$-0.53 - $0.21-70.59%Miss5
    No revisions (30d)
    		+63.3%

    Key Metrics

    Valuation
    P/E Ratio-1.27EV/EBITDAN/A
    Price/FCF-1.52xFCF Yield-66.00%
    Profitability
    Profit Margin0.00%Operating Margin-5007.00%
    ROE-54.10%ROIC-69.68%
    Financial Health
    Debt/Equity0.24xInterest Coverage-2.41x
    Current Ratio7.85xQuick Ratio7.85x
    Trading Statistics
    Beta-0.15Avg Volume425.39K
    52-Week High$16.4552-Week Low$4.11

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.73
    SMA 20$4.75
    SMA 50$5.80
    SMA 200$8.61
    EMA 10$4.78
    EMA 20$4.93
    EMA 50$5.58
    EMA 200$7.42

    MACD

    Line: -0.27Signal: -0.36Hist: 0.09

    ADX

    ADX: 22.7+DI: 17.0-DI: 17.1

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down32.0
    PSAR$4.19

    Bollinger Bands

    Upper Band$5.31
    Lower Band$4.18
    %B Position2389%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    47.7

    Momentum Oscillators

    Stoch %K57.0
    Stoch %D59.6
    Williams %R-37.4
    ROC (10d)10.9%
    Momentum0.48
    CCI (20d)9.2
    MFI (14d)51.0

    Volatility Measures

    ATR (14d)$0.48(9.8%)
    StdDev (20d)0.28
    Hist Vol127.2%(High)

    Volume Flow

    VWAP$4.78
    OBV-1.1M
    AD Line7.5M
    CMF (20d)0.101

    Volume Metrics

    Avg Vol (20d)439.4K
    Vol Ratio1.1x
    VWMA (20d)$4.75

    Pivot Points

    R3$5.46
    R2$5.26
    R1$4.91
    Pivot Point$4.71
    S1$4.35
    S2$4.16
    S3$3.80

    Advanced Oscillators

    TSI-13.69
    Ultimate Osc51.6
    KST-189.30

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$905,000$898,000$875,000$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M
    Cost of Revenue$0$0$0$886,000$0$0$0$992,000$0$0$0$736,000
    Gross Profit$905,000$898,000$875,000$1.30M$1.61M$1.95M$20.56M$37.40M$19.57M$94.69M$59.12M$41.85M
    Operating Expenses$42.59M$45.86M$43.18M$43.51M$48.66M$48.80M$42.35M$43.27M$41.23M$41.27M$38.01M$36.94M
    R&D$32.37M$35.37M$33.05M$33.96M$38.36M$37.88M$32.07M$33.41M$31.26M$32.03M$28.61M$28.29M
    SG&A$10.22M$10.49M$10.12M$9.55M$10.30M$10.92M$10.27M$9.86M$9.97M$9.24M$9.40M$8.65M
    Operating Income$-41,689,000$-44,963,000$-42,303,000$-42,208,000$-47,051,000$-46,849,000$-21,790,000$-5,867,000$-21,658,000$53.42M$21.11M$4.91M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$-1,974,000$-2,235,000$-2,624,000$0$-3,571,000$-3,924,000$-4,441,000$0$0$0$0$0
    Income Before Tax$-39,715,000$-42,728,000$-39,679,000$-39,072,000$-43,480,000$-42,925,000$-17,349,000$-739,000$-15,892,000$57.79M$25.33M$9.20M
    Income Tax Expense$27,000$35,000$38,000$92,000$654,000$178,000$0$-1,870,000$-1,860,000$2.76M$1.83M$18.74M
    Net Income$-39,742,000$-42,763,000$-39,717,000$-39,164,000$-44,134,000$-43,103,000$-17,349,000$1.13M$-14,032,000$55.03M$23.50M$-9,544,000
    EBITDA$-41,276,000$-44,572,000$-42,046,000$-41,955,000$-46,560,000$-46,776,000$-22,182,000$-7,382,000$-18,168,000$56.44M$24.22M$3.64M
    EBIT$-41,689,000$-44,963,000$-42,303,000$-42,208,000$-47,051,000$-46,849,000$-21,790,000$-5,867,000$-15,892,000$57.79M$25.33M$4.91M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TRDA

    News

    Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c

    Entrada Therapeutics, Inc. (TRDA) reported a Q3 EPS of ($0.94), surpassing the analyst estimate of ($1.01) by $0.07. However, the company's revenue for the quarter came in at $900 thousand...

    StreetInsider•11/5/26•Somewhat-Bullish

    Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates

    Entrada Therapeutics (TRDA) reported a narrower Q3 loss of $0.94 per share, surpassing the Zacks Consensus Estimate of a $0.98 loss...

    Yahoo Finance•11/5/26•Neutral

    Entrada Therapeutics Reports Q3 2026 Results, $193 Million in Cash

    Entrada Therapeutics announced its Q3 2026 financial results, reporting $0.9 million in collaboration revenue and a net loss of $39.7 million. The company ended the quarter with $193.0 million in cash, cash equivalents...

    TradingView•11/5/26•Neutral

    Revenue fell to $2.7M over nine months as Entrada Therapeutics (TRDA) widened its loss.

    Entrada Therapeutics (TRDA) reported a widened net loss of $122.2 million for the first nine months of 2026, compared to $104.6 million in the same period of 2025...

    Stock Titan•11/5/26•Bearish

    Entrada Therapeutics, Inc. (TRDA) Seasonal returns chart

    This article provides a seasonal returns chart for Entrada Therapeutics, Inc. (TRDA), displaying the average monthly price return from 2021 to 2026. The data is presented on Yahoo Finance...

    Yahoo Finance UK•10/30/26•Neutral

    TRDA Valuation and Fair Value

    P/E
    -1.3x
    Forward P/E
    3333.3x
    P/FCF
    -1.5x
    P/B
    1.0x
    See GNG's fair value

    TRDA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -5007.0%
    Net margin
    0.0%
    ROIC
    -69.7%
    ROE
    -54.1%
    FCF margin
    -3438.5%
    FCF yield
    -66.0%

    TRDA Competitors

    CompanyTicker
    Inogen IncINGN
    Upstream Bio, Inc.UPB
    Mediwound LtdMDWD
    Invivyd Inc.IVVD
    Exagen IncXGN
    Whitehawk Therapeutics, Inc.WHWK
    Bright Minds Biosciences IncDRUG
    PepGen LtdPEPG

    Sector: Healthcare

    TRDA Analyst Ratings

    Consensus
    Buy
    Analysts
    8
    Strong Buy
    0
    Buy
    7
    Hold
    1
    Sell
    0
    Strong Sell
    0

    TRDA Bull Case vs Bear Case

    Bull case

    • TRDA beat EPS estimates in 75.0% of its last 8 reported quarters.
    • 87.5% of TRDA's analyst ratings are Buy or Strong Buy.

    Bear case

    • TRDA's quarterly revenue changed -53.9% year over year.

    TRDA Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    21.4%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.88

    TRDA Earnings Date

    TRDA reports Feb 24, 2027, after the close. The date is estimated.

    TRDA ETF Holders

    GNG tracks 7 ETFs that hold TRDA. The largest weights:

    1. iShares Biotechnology ETF (IBB), 0.01% of the fund
    2. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.01% of the fund
    3. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    4. iShares Russell 2000 ETF (IWM), <0.01% of the fund
    5. Schwab U.S. Broad Market ETF (SCHB), <0.01% of the fund
    Open the ETF Stock Exposure tool for TRDA

    See insider activity

    Frequently Asked Questions About TRDA

    When does TRDA report earnings?

    Entrada Therapeutics Inc (TRDA) is expected to report earnings on Feb 24, 2027.

    Does TRDA pay dividends?

    Entrada Therapeutics Inc (TRDA) does not currently pay a regular dividend.

    What is TRDA's market cap?

    Entrada Therapeutics Inc (TRDA) has a market capitalization of $177.16M with a current stock price of $4.89.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In